We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-10.1%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$792M
AUM Growth
-$198M
Cap. Flow
-$87.5M
Cap. Flow %
-11.05%
Top 10 Hldgs %
71.73%
Holding
49
New
10
Increased
7
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$77.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.4M
3
SLDB icon
Solid Biosciences
SLDB
+$19M
4
XCUR icon
Exicure
XCUR
+$14.1M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$10.1M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$75.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$51.9M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.7M
4
KURA icon
Kura Oncology
KURA
+$22M
5
GOSS icon
Gossamer Bio
GOSS
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.64%
2 Miscellaneous 5.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
1
Xencor
XNCR
$1.94B
$84.4M 10.66%
2,501,557
+165,000
+7% +$6.59M
PRTA icon
2
Prothena Corp
PRTA
$479M
$73.9M 9.33%
9,426,640
+8,703,340
+1,203% +$77.3M
ONCE
3
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$69.3M 8.75%
714,789
+100,661
+16% +$10.1M
KURA icon
4
Kura Oncology
KURA
$1.13B
$61.3M 7.74%
4,041,953
-1,234,800
-23% -$22M
ARGX icon
5
argenx
ARGX
$64B
$60.5M 7.64%
531,165
-50,000
-9% -$6.76M
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$56.9M 7.19%
3,962,978
+646,571
+19% +$9.24M
KYNB
7
Kyntra Bio
KYNB
$32.5M
$47.8M 6.04%
51,752
-8,719
-14% -$9.58M
IRWD icon
8
Ironwood Pharmaceuticals
IRWD
$682M
$40.1M 5.06%
4,671,408
– –
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$39.1M 4.94%
2,161,520
-105,284
-5% -$2.21M
SLDB icon
10
Solid Biosciences
SLDB
$1.05B
$34.6M 4.36%
222,846
+167,713
+304% +$19M
PRVL
11
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$29.4M 3.71%
2,392,556
– –
KYNB
12
CALL
Kyntra Bio
KYNB
$32.5M
$24.1M 3.05%
26,100
+15,000
+135% +$16.5M
HARP
13
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$20M 2.52%
146,342
+11,500
+9% +$1.62M
BCEL
14
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$18.1M 2.29%
1,481,411
-5,568
-0.4% -$84.6K
CHMA
15
DELISTED
Chiasma, Inc. Common Stock
CHMA
$15.1M 1.9%
3,043,827
– –
SRPT icon
16
Sarepta Therapeutics
SRPT
$2.2B
$14.3M 1.8%
+189,745
New +$22.4M
XCUR icon
17
Exicure
XCUR
$8.44M
$14M 1.76%
+36,768
New +$14.1M
GOSS icon
18
CALL
Gossamer Bio
GOSS
$83.2M
$13.4M 1.7%
+800,000
New +$15.9M
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$10.9M 1.37%
35,335
-2,533
-7% -$823K
CYCN icon
20
Cyclerion Therapeutics
CYCN
$17.7M
$9.41M 1.19%
38,810
– –
NXTC icon
21
NextCure
NXTC
$27.9M
$7.73M 0.98%
+20,875
New +$6.79M
RCUS icon
22
Arcus Biosciences
RCUS
$3.72B
$6.87M 0.87%
754,505
-733,700
-49% -$5.9M
CRIS icon
23
Curis
CRIS
$3.61M
$6.68M 0.84%
7,456
– –
NGNE icon
24
Neurogene
NGNE
$732M
$6.46M 0.82%
113,294
– –
ASMB icon
25
CALL
Assembly Biosciences
ASMB
$694M
$4.9M 0.62%
41,525
– –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2019 Portfolio in Review

As of Q3 2019, EcoR1 Capital held 49 positions worth $792M, down 20% from $990M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital withdrew a net $87.5M in Q3 2019, closing 11 positions and reducing 13 holdings. Its most notable exit was CRISPR Therapeutics, an estimated $75.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Sarepta Therapeutics worth $14.3M.

  • EcoR1 Capital's largest Q3 2019 buy was Sarepta Therapeutics: 189,745 shares worth $14.3M.
  • EcoR1 Capital added most to Prothena Corp in Q3 2019, an estimated $77.3M increase.
  • EcoR1 Capital's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $51.9M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q3 2019, selling an estimated $75.8M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $792M portfolio in Q3 2019.
  • EcoR1 Capital opened 10 new positions and closed 11 in Q3 2019.
  • EcoR1 Capital's portfolio value fell 20% quarter-over-quarter to $792M.

Based on EcoR1 Capital's 13F filing for Q3 2019, filed 14 Nov 2019.